Work Here?
Overview
Novoic uses artificial intelligence to analyze spoken language to detect early signs of Alzheimer’s disease. It offers a software-based 10-minute speech test that runs on any smart device and is used by medical institutions, with 50+ centers currently adopting the technology. The company aims to extend access to underserved communities where detection is scarce. Revenue comes from selling the software to healthcare providers. Its AI models are validated through Novoic’s own clinical trials and trained on diverse datasets to improve accuracy and fairness.
About Novoic
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
1-10
Company Stage
Seed
Total Funding
$2.6M
Headquarters
London, United Kingdom
Founded
2019
Get referred to Novoic
See people who can refer or advise you
Simplify's Take
What believers are saying
- Novoic’s website updated March 2026 highlights 50+ institutions already using its tools.
- Its 2022-2025 publications claim prediction of MCI, preclinical AD, and amyloid PET positivity.
- Underserved-community screening and remote testing fit primary-care workflows and digital health budgets.
What critics are saying
- Novoic still lists only $2.68M raised, limiting clinical and commercial scale.
- Speech-biomarker adoption depends on NHS, ADNI, and ADDF translation into reimbursed devices.
- Deep-pocketed competitors can outspend Novoic on datasets, trials, and regulatory filings.
What makes Novoic unique
- Novoic runs speech biomarkers for Alzheimer's detection across 50+ institutions.
- Its AMYPRED studies validated biomarker-confirmed early-stage Alzheimer’s speech signals in UK and US.
- Novoic offers API access for ASR, quality control, and biomarkers, easing integration.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$2.6M
Below
Industry Average
Funded Over
1 Rounds
Industry standards
Company News
Novoic Raises £2 Million Seed Investment for AI-based Speech Analysis to Detect Neurological Diseases Earlier Anthemis Exponential Ventures leads the round, with participation from APEX Ventures and Entrepreneur First LONDON, July 31, 2020 Novoic, a digital biotechnology company developing speech-based AI algorithms for diagnosis and monitoring of health conditions, today announced it has raised £2.0 million in Seed funding […]
Novoic, a digital biotechnology company developing speech-based AI algorithms for diagnosis and monitoring of health conditions, today announced it has raised £2.0 million in Seed funding to scale up its AI research team and advance its clinical programmes, including in early-stage Alzheimer's and Parkinson's disease.
There are no jobs for Novoic right now.
Find jobs on Simplify and start your career today
About Novoic
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
1-10
Company Stage
Seed
Total Funding
$2.6M
Headquarters
London, United Kingdom
Founded
2019
There are no jobs for Novoic right now.
Find jobs on Simplify and start your career today